FDA Approves PROCHLORPERAZINE EDISYLATE — Somerset Therapeutics, LLC
Somerset Therapeutics, LLC announced the September 13, 2024 approval of its and for prochlorperazine edisylate, signalling a robust pipeline that positions the company to meet a significant unmet medical need. This market entrant establishes an important competitive alternative in the intramuscular treatment space, along with expanding Somerset's portfolio in the generic pharmaceutical sector.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day